Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Description

The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy. The main question it aims to answer is: • Does mavacamten treatment improve blood flow in the heart muscle? Participants will take mavacamten at the direction of their treating physician. Participants will complete 2 myocardial Positron Emission Tomography and Computed Tomography (PET-CT) scans. The first scan will be completed before participants start taking mavacamten. The scan will be repeated after 12 months of mavacamten treatment.

Conditions

Obstructive Hypertrophic Cardiomyopathy

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy. The main question it aims to answer is: • Does mavacamten treatment improve blood flow in the heart muscle? Participants will take mavacamten at the direction of their treating physician. Participants will complete 2 myocardial Positron Emission Tomography and Computed Tomography (PET-CT) scans. The first scan will be completed before participants start taking mavacamten. The scan will be repeated after 12 months of mavacamten treatment.

Coronary Flow Reserve in oHCM Patients Before and After 12 Months of Standard-of-care Mavacamten Treatment as Assessed by PET/CT

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Condition
Obstructive Hypertrophic Cardiomyopathy
Intervention / Treatment

-

Contacts and Locations

Charlottesville

University of Virginia, Charlottesville, Virginia, United States, 22908

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Willingness and ability to provide written informed consent
  • 2. Willingness and ability to comply with scheduled visits and study procedures
  • 3. Male or female, aged 18-85 years
  • 4. Diagnosed with obstructive hypertrophic cardiomyopathy according to presence of a left ventricular wall thickness of ≥15 mm that is otherwise unexplained by abnormal loading conditions (e.g., hypertension, valvular, congenital disease) or infiltrative cardiomyopathies. Unexplained left ventricular wall thickness of ≥13 mm is sufficient for diagnosis in relatives of individuals with hypertrophic cardiomyopathy or those who are genotype positive.
  • 5. Has been prescribed mavacamten consistent with US Prescribing Information
  • 6. Ability and intention to adhere to oral mavacamten therapy as prescribed by treating physician for the duration of study participation
  • 7. For females of reproductive potential: negative pregnancy test at screening/baseline and 12 month visits.
  • 1. Pregnancy or lactation
  • 2. Known hypersensitivity to components of mavacamten or regadenoson
  • 3. Prior treatment with mavacamten or aficamten
  • 11. Over weight limit for imaging gantry. 12. To minimize the risk of participants undergoing PET/CT with inadequate image quality, participants with left ventricular systolic dysfunction or lung disease will be excluded.

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Michael Ayers,

Study Record Dates

2026-09-30